Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation

Eric B. Hoie; Karen K. O’Brien; Katie Neighbors; Shana L. Castillo; Kimberley J. Begley

Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation

Eric B. Hoie, Karen K. O’Brien, Katie Neighbors, Shana L. Castillo, Kimberley J. Begley

Department of Pharmacy Practice

Research output: Contribution to specialist publication › Article

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.

Original language	English (US)
Pages	32-35
Number of pages	4
Volume	42
No	2
Specialist publication	U.S. Pharmacist
State	Published - Feb 2017

All Science Journal Classification (ASJC) codes

Pharmacy
Pharmacology
Pharmaceutical Science

Access to Document

Fingerprint Dive into the research topics of 'Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation'. Together they form a unique fingerprint.

Cite this

@misc{443ba2fb4e824043b91a399b204a14b0,

title = "Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation",

abstract = "Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient{\textquoteright}s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.",

author = "Hoie, {Eric B.} and O{\textquoteright}Brien, {Karen K.} and Katie Neighbors and Castillo, {Shana L.} and Begley, {Kimberley J.}",

year = "2017",

month = feb,

language = "English (US)",

volume = "42",

pages = "32--35",

journal = "U.S. Pharmacist",

issn = "0148-4818",

publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation

AU - Hoie, Eric B.

AU - O’Brien, Karen K.

AU - Neighbors, Katie

AU - Castillo, Shana L.

AU - Begley, Kimberley J.

PY - 2017/2

Y1 - 2017/2

N2 - Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.

AB - Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.

UR - http://www.scopus.com/inward/record.url?scp=85013946037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013946037&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85013946037

VL - 42

SP - 32

EP - 35

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -